144 related articles for article (PubMed ID: 35422427)
1. "Target inhibition of galectin-3 by inhaled TD139 in patients with idiopathic pulmonary fibrosis." Nikhil Hirani, Alison C. MacKinnon, Lisa Nicol,
Eur Respir J; 2022 Apr; 59(4):. PubMed ID: 35422427
[No Abstract] [Full Text] [Related]
2. Target inhibition of galectin-3 by inhaled TD139 in patients with idiopathic pulmonary fibrosis.
Hirani N; MacKinnon AC; Nicol L; Ford P; Schambye H; Pedersen A; Nilsson UJ; Leffler H; Sethi T; Tantawi S; Gravelle L; Slack RJ; Mills R; Karmakar U; Humphries D; Zetterberg F; Keeling L; Paul L; Molyneaux PL; Li F; Funston W; Forrest IA; Simpson AJ; Gibbons MA; Maher TM
Eur Respir J; 2021 May; 57(5):. PubMed ID: 33214209
[TBL] [Abstract][Full Text] [Related]
3. Selective Myeloid Depletion of Galectin-3 Offers Protection Against Acute and Chronic Lung Injury.
Humphries DC; Mills R; Dobie R; Henderson NC; Sethi T; Mackinnon AC
Front Pharmacol; 2021; 12():715986. PubMed ID: 34526900
[No Abstract] [Full Text] [Related]
4. "The therapy of idiopathic pulmonary fibrosis: what is next?" Vivien Somogyi, Nazia Chaudhuri, Sebastiano Emanuele Torrisi,
Eur Respir Rev; 2019 Sep; 28(153):. PubMed ID: 31554706
[No Abstract] [Full Text] [Related]
5. Efficient synthesis of a galectin inhibitor clinical candidate (TD139) using a Payne rearrangement/azidation reaction cascade.
St-Gelais J; Denavit V; Giguère D
Org Biomol Chem; 2020 May; 18(20):3903-3907. PubMed ID: 32400847
[TBL] [Abstract][Full Text] [Related]
6. "Baseline characteristics of idiopathic pulmonary fibrosis: analysis from the Australian Idiopathic Pulmonary Fibrosis Registry." Helen E. Jo, Ian Glaspole, Christopher Grainge, Nicole Goh, Peter M.A. Hopkins, Yuben Moodley, Paul N. Reynolds, Sally Chapman, E. Haydn Walters, Christopher Zappala, Heather Allan, Gregory J. Keir, Andrew Hayen, Wendy A. Cooper, Annabelle M. Mahar, Samantha Ellis, Sacha Macansh and Tamera J. Corte.
Eur Respir J; 2017 Mar; 49(3):. PubMed ID: 28356377
[No Abstract] [Full Text] [Related]
7. Progression and prognostic indicators of bronchial disease in children with sickle cell disease.
Williams SN; Nussbaum E; Yoonessi L; Morphew T; Randhawa I
Lung; 2014 Jun; 192(3):385-93. PubMed ID: 24699774
[TBL] [Abstract][Full Text] [Related]
8. "Mendelian randomisation and experimental medicine approaches to interleukin-6 as a drug target in pulmonary arterial hypertension." Mark Toshner, Colin Church, Lars Harbaum,
Eur Respir J; 2022 Jul; 60(1):. PubMed ID: 35798371
[No Abstract] [Full Text] [Related]
9. "Terguride ameliorates monocrotaline-induced pulmonary hypertension in rats." R. Dumitrascu, C. Kulcke, M. Königshoff,
Eur Respir J; 2021 Dec; 58(6):. PubMed ID: 34916252
[No Abstract] [Full Text] [Related]
10. "Safety of nintedanib added to pirfenidone treatment for idiopathic pulmonary fibrosis." Kevin R. Flaherty, Charlene D. Fell, J. Terrill Huggins, Hilario Nunes, Robert Sussman, Claudia Valenzuela, Ute Petzinger, John L. Stauffer, Frank Gilberg, Monica Bengus and Marlies Wijsenbeek.
Eur Respir J; 2018 Oct; 52(4):. PubMed ID: 30287496
[No Abstract] [Full Text] [Related]
11. "Unfavourable effects of medically indicated oral anticoagulants on survival in idiopathic pulmonary fibrosis." Michael Kreuter, Marlies S. Wijsenbeek, Martina Vasakova, Paolo Spagnolo, Martin Kolb, Ulrich Costabel, Derek Weycker, Klaus-Uwe Kirchgaessler and Toby M. Maher. Eur Respir J 2016; 47: 1776-1784.
Eur Respir J; 2016 Aug; 48(2):593. PubMed ID: 27478193
[No Abstract] [Full Text] [Related]
12. Pulmonary rehabilitation in idiopathic pulmonary fibrosis: a call for continued investigation.
Swigris JJ; Brown KK; Make BJ; Wamboldt FS
Respir Med; 2008 Dec; 102(12):1675-80. PubMed ID: 18848771
[TBL] [Abstract][Full Text] [Related]
13. "Cellular sources of interleukin-6 and associations with clinical phenotypes and outcomes in pulmonary arterial hypertension." Catherine E. Simpson, Jenny Y. Chen, Rachel L. Damico,
Eur Respir J; 2022 Apr; 59(4):. PubMed ID: 35484798
[No Abstract] [Full Text] [Related]
14. "Aberrant anti-viral response of natural killer cells in severe asthma." J. Devulder, C. Chenivesse, V. Ledroit,
Eur Respir J; 2024 Mar; 63(3):. PubMed ID: 38548273
[No Abstract] [Full Text] [Related]
15. "From pre-COPD to COPD: a Simple, Low cost and easy to IMplement (SLIM) risk calculator." M.J. Divo, C. Liu, F. Polverino,
Eur Respir J; 2023 Oct; 62(4):. PubMed ID: 37857431
[No Abstract] [Full Text] [Related]
16. "Spatial transcriptomics for respiratory research and medicine." S. Curras-Alonso, J. Soulier, T. Walter,
Eur Respir J; 2023 Feb; 61(2):. PubMed ID: 36822638
[No Abstract] [Full Text] [Related]
17. "Antifibrotic therapy for fibrotic lung disease beyond idiopathic pulmonary fibrosis." Bridget F. Collins and Ganesh Raghu.
Eur Respir Rev; 2019 Dec; 28(154):. PubMed ID: 31722893
[No Abstract] [Full Text] [Related]
18. "Long-term clinical and real-world experience with pirfenidone in the treatment of idiopathic pulmonary fibrosis." Vincent Cottin and Toby Maher. Eur Respir Rev 2015; 24: 58-64.
Eur Respir Rev; 2015 Sep; 24(137):545. PubMed ID: 26324819
[No Abstract] [Full Text] [Related]
19. "Recent lessons learned in the management of acute exacerbation of idiopathic pulmonary fibrosis." Yasuhiro Kondoh, Vincent Cottin and Kevin K. Brown.
Eur Respir Rev; 2018 Jun; 27(148):. PubMed ID: 29653947
[No Abstract] [Full Text] [Related]
20. "Age-related changes in plasma biomarkers and their association with mortality in COVID-19." E.H.A. Michels, B. Appelman, J. de Brabander,
Eur Respir J; 2024 Feb; 63(2):. PubMed ID: 38423593
[No Abstract] [Full Text] [Related]
[Next] [New Search]
